The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A patient-derived xenograft (PDX) platform to optimize omics-driven precision medicine in bladder cancer.
Chong-xian Pan
Research Funding - Abbott Laboratories; Novartis
Hongyong Zhang
No relevant relationships to disclose
Clifford Tepper
No relevant relationships to disclose
Paramita Ghosh
No relevant relationships to disclose
Sheri Kuslak-Meyer
No relevant relationships to disclose
Susan D. Airhart
No relevant relationships to disclose
David R. Gandara
No relevant relationships to disclose
Edison T. Liu
No relevant relationships to disclose
Ralph deVere White
No relevant relationships to disclose